Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial

Fereshteh Ashtari, Mohammad Reza Savoj, Fereshteh Ashtari, Mohammad Reza Savoj

Abstract

Background: Methotrexate, a toxic antimetabolite that limits cellular reproduction by acting as an antagonist to folic acid, has been used to control autoimmune disease with different results. The aim of this study was to evaluate the effectiveness of low dose Methotrexate in the relapsing-remitting multiple sclerosis (RRMS).

Methods: Eighty patients with definite RRMS aged 15 to 55 years were randomly allocated to receive a 12-month treatment course of either oral Methotrexate (7.5 mg/week) or intramuscular Interferon β-1α (30 μg/week). Response to treatment was assessed at 12 months after start of therapy.

Results: The results of the study demonstrated significant reduction in relapse rate in both groups (p < 0.01). In 40 patients treated by Methotrexate, the mean value (SD) of relapse rate decreased from 1.75 (0.74) to 0.97 (0.83) (p < 0.01). Correspondingly, the mean value (SD) of relapse rate in patients treated by Interferon β-1α decreased from 1.52 (0.59) to 0.57 (0.78) (p < 0.01). Decrease of relapse rate in Interferon β-1α group was more than that in the other group (p = 0.06).

Conclusions: This study suggests that although treatment with Methotrexate may significantly reduce relapse rate and slow progression of disease in patients with RRMS, its efficacy is less than Interferon β-1α and it may be better used as add-on therapy.

Keywords: Interferon Beta; Methotrexate; Multiple Sclerosis.

Conflict of interest statement

Conflict of Interests

Authors have no conflict of interests.

References

    1. Clanet MG, Brassat D. The management of multiple sclerosis patients. Curr Opin Neurol. 2000;13(3):263–70.
    1. Nicholas R, Chataway J. Multiple sclerosis. Clin Evid (Online) 2007 Aug 15;:pii–1202.
    1. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess. 2002;6(10):1–73.
    1. Polman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. West J Med. 2000;173(6):398–402.
    1. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs. 2005;19(3):239–52.
    1. Miller A. Current and investigational therapies used to alter the course of disease in multiple sclerosis. South Med J. 1997;90(4):367–75.
    1. Myhr KM. Pharmacological treatment of multiple sclerosis. Tidsskr Nor Laegeforen. 2010;130(5):490–2. [In Spanish]
    1. Ransohoff RM. PML risk and natalizumab: more questions than answers. Lancet Neurol. 2010;9(3):231–3.
    1. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004;18(6):379–96.
    1. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry. 2008;79(1):52–6.
    1. O’Connor PW. Use of natalizumab in multiple sclerosis patients. Can J Neurol Sci. 2010;37(1):98–104.
    1. Menge T, Weber MS, Hemmer B, Kieseier BC, von Budingen HC, Warnke C. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008;68(17):2445–68.
    1. Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs. 2009;18(7):985–9.
    1. Warnke C, Meyer Zu HG, Hartung HP, Stuve O, Kieseier BC. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009;5:333–40.
    1. Zaffaroni M, Ghezzi A, Comi G. Intensive immunosuppression in multiple sclerosis. Neurol Sci. 2006;27(Suppl 1):S13–7.
    1. Goodkin DE, Rudick RA, VanderBrug MS, Daughtry MM, Van Dyke C. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology. 1996;47(5):1153–7.
    1. Lugaresi A, Caporale C, Farina D, Marzoli F, Bonanni L, Muraro PA, et al. Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. Neurol Sci. 2001;22(2):209–10.
    1. Gray OM, McDonnell GV, Forbes RB. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler. 2006;12(4):507–10.
    1. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005;114(2):154–63.
    1. Jeffery DR. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology. 2004;63(12 Suppl 6):S41–6.
    1. Hommes OR, Weiner HL. Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis. Mult Scler. 2002;8(2):139–41.
    1. Fernandez O, Fernandez V, De Ramon E. Azathioprine and methotrexate in multiple sclerosis. J Neurol Sci. 2004;223(1):29–34.
    1. Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry. 2001;70(5):574–9.
    1. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs. 2005;19(5):369–76.
    1. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227–31.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33(11):1444–52.
    1. Goodkin DE, Rudick RA, VanderBrug MS, Daughtry MM, Schwetz KM, Fischer J, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995;37(1):30–40.
    1. Bernatsky S, Ehrmann FD. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Quebec, Canada. Drugs Aging. 2008;25(10):879–84.
    1. Florea A, Job-Deslandre C. [Rheumatoid arthritis and pregnancy] Presse Med. 2008;37(11):1644–51.
    1. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59(8):1074–81.
    1. Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry. 1993;56(11):1217–8.
    1. Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology. 2002;58(2):314–7.
    1. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron. 1999;24(3):511–4.
    1. McDevitt H. Specific antigen vaccination to treat autoimmune disease. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14627–30.
    1. Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology. 1995;45(6 Suppl 6):S11–5.
    1. Cua DJ, Hinton DR, Stohlman SA. Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease. J Immunol. 1995;155(8):4052–9.
    1. Weiner HL, Friedman A, Miller A, Khoury SJ, al Sabbagh A, Santos L, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994;12:809–37.
    1. Zhang GX, Xu H, Kishi M, Calida D, Rostami A. The role of IL-12 in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis. J Immunol. 2002;168(5):2501–7.
    1. Zhang GX, Yu S, Li Y, Ventura ES, Gran B, Rostami A. A paradoxical role of APCs in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005;161(1-2):101–12.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться